Manipal Hospitals Q1 FY27: Strong volume-led growth with Sahyadri adding scale

Manipal Health Enterprises Limited reported its first quarterly results after listing on August 5, 2026, and the numbers show a network that is growing quickly while absorbing new capacity. For the quarter ended June 30, 2026, revenue from operations rose to ₹3,091 crore, up 38.1 percent year on year. EBITDA increased to ₹749 crore, up 26.4 percent year on year. Profit after tax came in at ₹243 crore.

The headline growth is supported by patient volumes and rising occupancy. Inpatient volumes grew 38.8 percent and outpatient volumes grew 26.0 percent. Occupancy improved to 65.0 percent, up 290 basis points year on year. The story is not only about more patients. It is also about the kind of care delivered. The company highlighted continued momentum in high-acuity specialties, with CONGO-R specialties accounting for 65.4 percent of gross inpatient revenue.

Management framed the quarter as both a performance update and a milestone. MD and CEO Dilip Jose said the results reflect the strength of the pan-India network, sustained patient demand, and growth in high-acuity specialties, while the company stays focused on absorbing added capacity and maintaining clinical quality and operational discipline. That framing is useful for investors because the quarter includes the impact of the Sahyadri acquisition, and therefore mixes integration execution with underlying operating trends.

Growth drivers: volumes, occupancy, and higher-acuity mix

The fastest moving indicators in the quarter were volumes and capacity utilization. Operational beds increased to 7,164 in Q1 FY27 from 5,430 in Q1 FY26, reflecting a larger footprint after network additions. Occupied beds rose to 4,657 from 3,374, and occupancy moved to 65.0 percent from 62.1 percent. Average length of stay remained stable at 2.7 days, which suggests that higher throughput did not come from longer admissions.

Revenue intensity, measured through ARPOB, looks muted at the consolidated level because Sahyadri carries a lower ARPOB than the rest of the network. Reported ARPOB was ₹71,500 per day versus ₹71,000 per day in Q1 FY26, up 0.7 percent. But excluding Sahyadri, ARPOB was ₹77,200 per day, up 8.7 percent year on year. Investors should read this as a sign that the existing network is improving yield even as consolidated averages get pulled down by the acquired platform.

The specialty mix reinforces this theme. CONGO-R specialties contributed 65.4 percent of gross inpatient revenue in Q1 FY27 compared with 64.7 percent in Q1 FY26. Within that, Oncology and Orthopedics stood out, with inpatient revenue growth of 62 percent and 49 percent year on year, respectively. The company also reported year on year growth in other CONGO-R specialties such as Cardiac at 40 percent, Neuro at 39 percent, Gastro at 35 percent, and Renal at 41 percent. A higher-acuity mix typically supports stronger pricing power and more complex case throughput, which matters as occupancy rises.

The margin line is the key trade-off in the quarter. EBITDA margin declined to 24.2 percent from 26.5 percent in Q1 FY26. Part of the comparison is affected by a one-off gain of ₹15 crore in Q1 FY26. Excluding that gain, Q1 FY26 adjusted EBITDA was ₹578 crore, which implies Q1 FY27 adjusted EBITDA growth of 29.7 percent year on year. Still, margin compression remains visible even after adjusting for one-offs, and it points to the cost of scaling and integrating a larger network.

PAT is also affected by financing structure related to the acquisition. The company noted that PAT excluding net post-tax interest on the NCD raised for the Sahyadri acquisition would have been ₹332 crore, and that this adjusted PAT grew 30.9 percent year on year. The reported PAT of ₹243 crore therefore reflects the interest burden rather than deterioration in core operating performance.

Sahyadri: scale added, integration becomes the next variable

Sahyadri’s contribution is large enough to change consolidated metrics and small enough that execution will determine whether it becomes an earnings catalyst. In Q1 FY27, Manipal Hospitals reported that the quarter includes Sahyadri revenue of ₹332 crore and Sahyadri EBITDA of ₹58 crore. Sahyadri itself recorded 12.8 percent revenue growth and 18.7 percent EBITDA growth year on year on its erstwhile management reporting base, supported by higher ARPOB and improved operating efficiency.

Sahyadri’s operational profile helps explain the blended ARPOB outcome. Sahyadri reported ARPOB of ₹44,800 per day, up 14.7 percent year on year. Occupancy was 62.6 percent, down 100 basis points year on year but up 110 basis points versus Q4 FY26. ALOS was 2.8 days, down 7.6 percent year on year. Those numbers indicate improving throughput and pricing, even if occupancy has not yet reached the levels of the broader network.

The integration plan is structured around measurable workstreams. Procurement synergies have moved into execution with centralized pricing rates rolled out. The company is also targeting efficiencies through OP to IP conversion and service excellence. Branding is being handled through co-branding and a phased introduction of digital revenue initiatives. On people and governance, regional leadership and grade alignment are in place, alongside clinical talent additions of 82 and clinician interoperability of 58. Governance upgrades include Big Four quarterly audit and internal audit processes, cybersecurity assessments including VAPT and DDPD, and life fire and safety audits.

For investors, the practical implication is that the company is emphasizing controllable levers first, such as procurement and governance, before pushing for heavier clinical integration and productivity gains. That sequencing typically reduces integration risk, but it can also mean that margin benefits take time to show up.

A larger network with rising capacity utilization

Manipal Hospitals positions itself as India’s largest pan-India multi-specialty hospital network by bed capacity, with 13,140 licensed beds across 49 hospitals as of June 30, 2026. The network includes 11,000 plus doctors and 24,700 plus employees. The company also reports a pan-India footprint across 14 states and union territories.

The network map matters because it shows where utilization gains can come from. Karnataka remains the anchor region, with Q1 FY27 revenue of ₹1,373 crore versus ₹1,115 crore in Q1 FY26. Operational beds rose to 2,294 from 2,028, but occupancy was stable at 61.1 percent versus 60.9 percent. That suggests Karnataka is expanding capacity while holding utilization.

The Maharashtra plus Goa region shows the largest reported step-up, with revenue increasing to ₹503 crore from ₹127 crore and operational beds rising to 1,680 from 352. Occupancy improved sharply to 62.5 percent from 54.8 percent, and IP volume increased to 35,000 from 7,000. This is consistent with Sahyadri being integrated into this region’s base.

East India saw steadier progress, with revenue increasing to ₹620 crore from ₹530 crore. Beds were nearly flat at 1,858 versus 1,855, while occupancy improved to 66.9 percent from 63.8 percent. Rest of India improved both on revenue and utilization, with revenue increasing to ₹535 crore from ₹407 crore and occupancy rising to 72.3 percent from 63.8 percent.

These region metrics exclude HealthMap revenue, which was ₹59 crore in both Q1 FY26 and Q1 FY27. That stability implies that the quarter’s growth is driven by the hospital business rather than a swing in ancillary streams.

What the financial statements say about operating discipline

The income statement shows the mechanics behind growth and margin movement. Revenue from operations was ₹3,090.6 crore. Costs scaled with growth, with cost of materials consumed at ₹626.1 crore and employee benefits expense excluding ESOP expenses at ₹449.6 crore. Other expenses were ₹1,265.9 crore. EBITDA was ₹749.0 crore, and ESOP expenses were ₹12.4 crore.

Below EBITDA, finance costs are the main swing factor, at ₹293.3 crore in Q1 FY27 versus ₹131.6 crore in Q1 FY26. Depreciation and amortization increased to ₹187.2 crore from ₹140.6 crore, consistent with a larger asset base and expanded network. Other income was ₹74.6 crore, higher than ₹48.4 crore in Q1 FY26.

Exceptional items were negative at ₹15.5 crore. Profit before tax was ₹315.2 crore and tax expense was ₹71.8 crore, resulting in reported PAT of ₹243.4 crore.

From an investor lens, the quarter shows a company in a transition phase. Operating earnings are rising on patient demand and specialty momentum. But reported profits are sensitive to acquisition financing, and margins are being shaped by the integration of a newly acquired platform and the costs of scale.

Clinical capability and equipment: supporting the acuity strategy

Manipal Hospitals used the presentation to underline that growth is being paired with clinical capabilities. It highlighted network additions in Q1 FY27 such as high-end LINAC and PET CT at Manipal Hospitals Nashik, an AI-assisted neuro biplane cath lab system at Manipal Hospitals Mukundpur, orthopedic robots at Patiala, Vijayawada and Pune Baner, and an AI-enabled cath lab system at Old Airport Road.

The company listed installed equipment counts across the network, including 19 LINACs, 2 tomotherapy units, 25 orthopedic and spine surgical robots, 59 cath labs, 44 MRI machines, and 19 soft tissue robots. It also cited clinical milestones across hospitals, including complex pediatric robotic pancreatic surgery, emergency living donor liver transplant, robotic renal transplants, robotic cardiac cases, and complex cardiovascular interventions.

These details matter because the company is leaning on high-acuity specialties for growth. Equipment density and advanced capability can support referrals, improve case complexity, and strengthen the network effect across hubs such as Bengaluru, Kolkata, and Pune.

Investor takeaways: the quarter’s message is scale with execution

Q1 FY27 shows a hospital platform that is growing faster than the industry headline would suggest, driven by higher volumes, improving occupancy, and a specialty mix weighted toward complex care. Revenue growth of 38.1 percent and EBITDA growth of 26.4 percent are strong for a network also integrating a major acquisition.

At the same time, the quarter makes clear where investors should focus next. First, margin trajectory, because EBITDA margin has moved down to 24.2 percent and the integration could keep consolidated margins under pressure until synergies and productivity gains show up. Second, financing impact, because reported PAT is held back by the NCD interest related to Sahyadri, even though adjusted PAT is materially higher. And third, the pace of utilization gains, because occupancy at 65.0 percent shows progress, but a large and expanding bed base leaves room for further absorption.

The company’s stated priorities fit this setup: absorb added capacity, protect clinical quality, and execute a structured Sahyadri integration plan that targets procurement, governance, and operational efficiency. If those elements move in the right direction, Manipal Hospitals could convert the current phase of expansion into more durable earnings growth in future quarters.